Bridging anticoagulation therapy
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F18%3A10380142" target="_blank" >RIV/00216208:11140/18:10380142 - isvavai.cz</a>
Alternative codes found
RIV/00669806:_____/18:10380142
Result on the web
<a href="https://doi.org/10.1016/j.crvasa.2018.04.002" target="_blank" >https://doi.org/10.1016/j.crvasa.2018.04.002</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.crvasa.2018.04.002" target="_blank" >10.1016/j.crvasa.2018.04.002</a>
Alternative languages
Result language
angličtina
Original language name
Bridging anticoagulation therapy
Original language description
Oral anticoagulation therapy is used in patients with various diagnoses to reduce the risk of thromboembolic events or to induce a hypocoagulation state to facilitate dissolution of a thrombus. In clinical practice we often encounter anticoagulated patients, many of whom have been diagnosed with nonvalvular atrial fibrillation. Each year a significant number of these patients undergo a medical procedure, which, in some cases, requires temporary discontinuation of anticoagulation therapy. However without anticoagulation therapy, the patient is at increased risk of thromboembolic events. Therefore, parenteral anticoagulants with fast onset and rapid cessation of action can be used to reduce risk while patients are without adequate oral anticoagulation. Here we summarized the currently available data, which has been drawn from guidelines and other expert documents of European Society of Cardiology (ESC), American College of Cardiology (ACC) and American College of Chest Physicians (CHEST). The vast majority of available studies, including the only single randomized, double-blind, placebo-controlled BRIDGE trial, report an increased risk of major bleeding in patients on bridging therapy. A subanalysis of the RE-LY trial, also found that thromboembolic risk in patients with bridging therapy was significantly higher. The most detailed recommendation for use of bridging therapy in patients with nonvalvular atrial fibrillation was provided by the 2017 Expert Consensus of the ACC, while the ESC only marginally discusses bridging therapy in their expert documents. Bridging is not generally necessary in patients taking non-vitamin K oral anticoagulants (NOACs), but if clinical circumstances require it, the risks and benefits are the same as with vitamin K antagonist (VKA) anticoagulation. Data on the use of NOACs for bridging therapy are scarce. (c) 2018 The Czech Society of Cardiology. Published by Elsevier Sp. z o.o. All rights reserved.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Cor et Vasa
ISSN
0010-8650
e-ISSN
—
Volume of the periodical
60
Issue of the periodical within the volume
4
Country of publishing house
CZ - CZECH REPUBLIC
Number of pages
7
Pages from-to
"E400"-"E406"
UT code for WoS article
000442902500010
EID of the result in the Scopus database
2-s2.0-85047201004